$QURE

Potts Jeannette sold $145K of QURE

Potts Jeannette (Chief Legal Officer) sold 5,237 shares of uniQure N.V. (QURE) at $27.67 ($0.14M total) on 2026-06-15.

Original reporting
SEC EDGAR · Potts Jeannette
Published Jun 17, 2026, 8:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$QURE
Neutral
medium confidence
Mentioned
$QURE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

This adds incremental transparency on insider activity but does not include operational, clinical, regulatory, or financial performance changes.

02

Market read

Traders may monitor for follow-on insider selling, but the disclosed transaction size and lack of accompanying fundamental catalysts suggest limited immediate trading impact.

03

What to watch

Insider sales can be driven by taxes, diversification, or pre-existing personal liquidity needs; the filing provides no rationale or forward guidance.

Relevance 4/10Novelty 5/10Timing: filed 2026-06-17 (covers sale dated 2026-06-15)

Background

The article is an SEC Form 4 insider transaction disclosure for uniQure N.V., reporting an officer’s open-market sale.

Company-level read

Ticker impact

$QURENeutralMedium confidence
Context

uniQure N.V. (QURE) disclosed an officer open-market sale: 5,237 shares sold on 2026-06-15 at $27.6700 for ~$144.9K.

Expected impact

Likely limited near-term impact; any reaction should be muted unless follow-on selling accelerates.

Evidence & confidence

Form 4 insider transactions are common and this one is modest in dollar value; absence of a 10b5-1 plan can raise attention but the disclosure alone rarely drives sustained repricing.

Market effects

No sector read-across; this is company-specific insider liquidity/portfolio activity.

None indicated.

None indicated.

Counterpoint

The lack of a pre-arranged 10b5-1 plan could be interpreted as less “scheduled” selling, potentially signaling management discretion rather than a planned cadence.

Key entities

  • uniQure N.V.

    Subject of the Form 4 insider sale disclosure.

  • Potts Jeannette

    Chief Legal Officer who sold 5,237 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$QUREHighAI 9/10

Gene Therapy Data Could Be A Big Moment For uniQure Stock (QURE)

uniQure (QURE) reported Phase I/II data for its Huntington’s disease gene therapy, showing slowed disease progression and a manageable safety profile. The FDA previously indicated that 36-month data could support an accelerated approval BLA. Analysts project significant revenue growth, with consensus estimates at $445.8M and earnings of $20.0M by 2029, though the company remains loss-making. The regulatory decision on the BLA is a key near-term focus for investors.

Med

UniQure Shares Fall After Barclays Downgrade

UniQure's shares declined after Barclays downgraded the company from Overweight to Equal Weight. The stock is currently trading at $22.81, down 2.77% on the day and 41.83% year-to-date. The downgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.

$QUREMedAI 8/10

RBC Capital cuts uniQure stock price target on trial data

RBC Capital reduced its price target for uniQure (QURE) to $48 from $65, citing trial data that missed statistical significance. The stock has fallen 39% in a week. Other analysts maintain bullish outlooks with higher targets. uniQure reported a wider-than-expected Q2 loss but revenue beat estimates. The company has FDA agreements for its Huntington’s disease gene therapy, AMT-130.